Cargando…
Calprotectin instability may lead to undertreatment in children with IBD
BACKGROUND: Treatment decisions in children with inflammatory bowel disease (IBD) are increasingly based on longitudinal tracking of faecal calprotectin concentrations, but there is little known about the stability of this protein in stool. METHODS: We stored aliquots of homogenised stool at room te...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513246/ https://www.ncbi.nlm.nih.gov/pubmed/30655264 http://dx.doi.org/10.1136/archdischild-2018-316584 |
_version_ | 1783586343859781632 |
---|---|
author | Haisma, Sjoukje-Marije van Rheenen, Patrick Ferry Wagenmakers, Lucie Muller Kobold, Anneke |
author_facet | Haisma, Sjoukje-Marije van Rheenen, Patrick Ferry Wagenmakers, Lucie Muller Kobold, Anneke |
author_sort | Haisma, Sjoukje-Marije |
collection | PubMed |
description | BACKGROUND: Treatment decisions in children with inflammatory bowel disease (IBD) are increasingly based on longitudinal tracking of faecal calprotectin concentrations, but there is little known about the stability of this protein in stool. METHODS: We stored aliquots of homogenised stool at room temperature and at 4°C, and measured the calprotectin concentration for 6 consecutive days with three different assays. In addition, we assessed calprotectin stability in assay-specific extraction buffers kept at room temperature. RESULTS: After 6 days of storage at room temperature, mean percentage change from baseline calprotectin concentrations in stool and extraction buffer was 35% and 46%, respectively. The stability of calprotectin was significantly better preserved in samples stored at 4°C (p=0.0066 and 0.0011, respectively). CONCLUSIONS: Calprotectin is not stable at room temperature. Children with IBD and their caretakers may be falsely reassured by low calprotectin values. The best advisable standard for preanalytical calprotectin handling is refrigeration of the stool sample until delivery at the hospital laboratory. |
format | Online Article Text |
id | pubmed-7513246 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-75132462020-10-05 Calprotectin instability may lead to undertreatment in children with IBD Haisma, Sjoukje-Marije van Rheenen, Patrick Ferry Wagenmakers, Lucie Muller Kobold, Anneke Arch Dis Child Short Report BACKGROUND: Treatment decisions in children with inflammatory bowel disease (IBD) are increasingly based on longitudinal tracking of faecal calprotectin concentrations, but there is little known about the stability of this protein in stool. METHODS: We stored aliquots of homogenised stool at room temperature and at 4°C, and measured the calprotectin concentration for 6 consecutive days with three different assays. In addition, we assessed calprotectin stability in assay-specific extraction buffers kept at room temperature. RESULTS: After 6 days of storage at room temperature, mean percentage change from baseline calprotectin concentrations in stool and extraction buffer was 35% and 46%, respectively. The stability of calprotectin was significantly better preserved in samples stored at 4°C (p=0.0066 and 0.0011, respectively). CONCLUSIONS: Calprotectin is not stable at room temperature. Children with IBD and their caretakers may be falsely reassured by low calprotectin values. The best advisable standard for preanalytical calprotectin handling is refrigeration of the stool sample until delivery at the hospital laboratory. BMJ Publishing Group 2020-10 2019-01-17 /pmc/articles/PMC7513246/ /pubmed/30655264 http://dx.doi.org/10.1136/archdischild-2018-316584 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Short Report Haisma, Sjoukje-Marije van Rheenen, Patrick Ferry Wagenmakers, Lucie Muller Kobold, Anneke Calprotectin instability may lead to undertreatment in children with IBD |
title | Calprotectin instability may lead to undertreatment in children with IBD |
title_full | Calprotectin instability may lead to undertreatment in children with IBD |
title_fullStr | Calprotectin instability may lead to undertreatment in children with IBD |
title_full_unstemmed | Calprotectin instability may lead to undertreatment in children with IBD |
title_short | Calprotectin instability may lead to undertreatment in children with IBD |
title_sort | calprotectin instability may lead to undertreatment in children with ibd |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513246/ https://www.ncbi.nlm.nih.gov/pubmed/30655264 http://dx.doi.org/10.1136/archdischild-2018-316584 |
work_keys_str_mv | AT haismasjoukjemarije calprotectininstabilitymayleadtoundertreatmentinchildrenwithibd AT vanrheenenpatrickferry calprotectininstabilitymayleadtoundertreatmentinchildrenwithibd AT wagenmakerslucie calprotectininstabilitymayleadtoundertreatmentinchildrenwithibd AT mullerkoboldanneke calprotectininstabilitymayleadtoundertreatmentinchildrenwithibd |